

heparin binding protein antibody, wherein said antibody binds to an epitope of heparin-binding protein which interacts with kininogen, in an amount effective to decrease release of bradykinin and in an amount effective to attenuate said alterations in endothelial cell permeability in said mammal.

54. (new) The method according to claim 53, wherein said mammal is a human patient and said HBP is human HBP.

55. (new) The method according to claim 53, wherein said antibody is a monoclonal antibody.

56. (new) The method according to claim 53, in which the antibody is present in an amount of from about 10 mg to about 1 g per unit dosage form.

57. (new) The method according to claim 53, in which the antibody is present in an amount of about 0.1-100 mg/kg body weight.

58. (new) The method according to claim 53, in which the antibody is present in an amount of about 0.5-50 mg/kg body weight.

59. (new) The method according to claim 53, in which the antibody is present in an amount of about 1-25 mg/kg body weight.

60. (new) The method according to claim 53, in which the disorder is selected from the group consisting of systemic inflammatory response syndrome, ischemia reperfusion, anaphylaxis and allograft rejection.